1
|
Jia Q, Xu L, Shen J, Wei Y, Xu H, Shi J, Jia Z, Zhao X, Liu C, Zhong Q, Tian Y, He K. Detecting Rare Variants and Heteroplasmy of Mitochondrial DNA from High-Throughput Sequencing in Patients with Coronary Artery Disease. Med Sci Monit 2020; 26:e925401. [PMID: 33132382 PMCID: PMC7646198 DOI: 10.12659/msm.925401] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background Although mutations and dysfunction of mitochondrial DNA (mtDNA) are related to a variety of diseases, few studies have focused on the relationship between mtDNA and coronary artery disease (CAD), especially the relationship between rare variants and CAD. Material/Methods Two-stage high-throughput sequencing was performed to detect mtDNA variants or heteroplasmy and the relationship between them and CAD phenotypes. In the discovery stage, mtDNA was analyzed by high-throughput sequencing of long-range PCR products generated from the peripheral blood of 85 CAD patients and 80 demographically matched controls. In the validation stage, high-throughput sequencing for mtDNA target regions captured by GenCap Kit was performed on 100 CAD samples and 100 controls. Finally, tRNA fine mapping was performed between our study and the reported Chinese CAD study. Results Among the tRNA genes, we confirmed a highly conserved rare variant, A5592G, previously reported in the Chinese CAD study, and 2 novel rare mutations that reached Bonferroni’s correction significance in the combined analysis were found (P=7.39×10−4 for T5628C in tRNAAla and P=1.01×10−5 for T681C in 12S rRNA) in the CAD study. Both of them were predicted to be pathological, with T5628C disrupting an extremely conservative base-pairing at the AC stem of tRNAAla. Furthermore, we confirmed the controversial issue that the number of non-synonymous heteroplasmic sites per sample was significantly higher in CAD patients. Conclusions In conclusion, our study confirmed the contribution of rare variants in CAD and showed that CAD patients had more non-synonymous heterogeneity mutations, which may be helpful in identifying the genetic and molecular basis of CAD.
Collapse
Affiliation(s)
- Qian Jia
- Core Laboratory of Translational Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland).,Beijing Key laboratory of Chronic Heart Failure Precision Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| | - Lu Xu
- Core Laboratory of Translational Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| | - Juan Shen
- BGI Genomics, Shenzhen, Guangdong, China (mainland)
| | - Yanping Wei
- BGI Genomics, Shenzhen, Guangdong, China (mainland)
| | - Huaiqian Xu
- BGI Genomics, Shenzhen, Guangdong, China (mainland)
| | - Jinlong Shi
- Beijing Key laboratory of Chronic Heart Failure Precision Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland).,Key Laboratory of Biomedical Engineering and Translational Medicine, Ministry of Industry and Information Technology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| | - Zhilong Jia
- Beijing Key laboratory of Chronic Heart Failure Precision Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland).,Key Laboratory of Biomedical Engineering and Translational Medicine, Ministry of Industry and Information Technology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| | - Xiaojing Zhao
- Core Laboratory of Translational Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland).,Beijing Key laboratory of Chronic Heart Failure Precision Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| | - Chunlei Liu
- Core Laboratory of Translational Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland).,Beijing Key laboratory of Chronic Heart Failure Precision Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| | - Qin Zhong
- Core Laboratory of Translational Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland).,Beijing Key laboratory of Chronic Heart Failure Precision Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| | - Yaping Tian
- Core Laboratory of Translational Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| | - Kunlun He
- Core Laboratory of Translational Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland).,Beijing Key laboratory of Chronic Heart Failure Precision Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland)
| |
Collapse
|
2
|
Mensah GA. The Journey From Research Discovery to Optimal Heart Health for All. Glob Heart 2018; 13:61-64. [PMID: 29627103 DOI: 10.1016/j.gheart.2018.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
Affiliation(s)
- George A Mensah
- Center for Translation Research and Implementation Science (CTRIS), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
| |
Collapse
|
3
|
A Changing Landscape in Cardiovascular Research Publication Output. J Am Coll Cardiol 2018; 71:1584-1589. [DOI: 10.1016/j.jacc.2018.01.073] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 01/26/2018] [Accepted: 01/28/2018] [Indexed: 11/20/2022]
|
4
|
Beierlein JM, McNamee LM, Walsh MJ, Kaitin KI, DiMasi JA, Ledley FD. Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities. Clin Ther 2017; 39:1409-1425.e20. [PMID: 28652015 DOI: 10.1016/j.clinthera.2017.06.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 05/23/2017] [Accepted: 06/05/2017] [Indexed: 12/22/2022]
Abstract
PURPOSE This study examines the complete timelines of translational science for new cardiovascular therapeutics from the initiation of basic research leading to identification of new drug targets through clinical development and US Food and Drug Administration (FDA) approval of new molecular entities (NMEs) based on this research. METHODS This work extends previous studies by examining the association between the growth of research on drug targets and approval of NMEs associated with these targets. Drawing on research on innovation in other technology sectors, where technological maturity is an important determinant in the success or failure of new product development, an analytical model was used to characterize the growth of research related to the known targets for all 168 approved cardiovascular therapeutics. FINDINGS Categorizing and mapping the technological maturity of cardiovascular therapeutics reveal that (1) there has been a distinct transition from phenotypic to targeted methods for drug discovery, (2) the durations of clinical and regulatory processes were significantly influenced by changes in FDA practice, and (3) the longest phase of the translational process was the time required for technology to advance from initiation of research to a statistically defined established point of technology maturation (mean, 30.8 years). IMPLICATIONS This work reveals a normative association between metrics of research maturation and approval of new cardiovascular therapeutics and suggests strategies for advancing translational science by accelerating basic and applied research and improving the synchrony between the maturation of this research and drug development initiatives.
Collapse
Affiliation(s)
- Jennifer M Beierlein
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Laura M McNamee
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Michael J Walsh
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts
| | - Kenneth I Kaitin
- Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts
| | - Joseph A DiMasi
- Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts
| | - Fred D Ledley
- Center for Integration of Science and Industry, Department of Natural & Applied Sciences, Bentley University, Waltham, Massachusetts; Department of Management, Bentley University, Waltham, Massachusetts.
| |
Collapse
|
5
|
Boudoulas KD, Triposkiadis F, Parissis J, Butler J, Boudoulas H. The Cardio-Renal Interrelationship. Prog Cardiovasc Dis 2017; 59:636-648. [DOI: 10.1016/j.pcad.2016.12.003] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Accepted: 12/11/2016] [Indexed: 12/14/2022]
|
6
|
Mensah GA, Galis ZS, Fine LJ, Garcia ME, Levy DF, Gibbons GH. Building on a Legacy of Hypertension Research: Charting Our Future Together. Hypertension 2017; 69:5-10. [PMID: 27849567 PMCID: PMC5145749 DOI: 10.1161/hypertensionaha.116.06582] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
7
|
Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. Cardiovascular drug development: is it dead or just hibernating? J Am Coll Cardiol 2015; 65:1567-82. [PMID: 25881939 DOI: 10.1016/j.jacc.2015.03.016] [Citation(s) in RCA: 136] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 03/03/2015] [Accepted: 03/03/2015] [Indexed: 12/19/2022]
Abstract
Despite the global burden of cardiovascular disease, investment in cardiovascular drug development has stagnated over the past 2 decades, with relative underinvestment compared with other therapeutic areas. The reasons for this trend are multifactorial, but of primary concern is the high cost of conducting cardiovascular outcome trials in the current regulatory environment that demands a direct assessment of risks and benefits, using clinically-evident cardiovascular endpoints. To work toward consensus on improving the environment for cardiovascular drug development, stakeholders from academia, industry, regulatory bodies, and government agencies convened for a think tank meeting in July 2014 in Washington, DC. This paper summarizes the proceedings of the meeting and aims to delineate the current adverse trends in cardiovascular drug development, understand the key issues that underlie these trends within the context of a recognized need for a rigorous regulatory review process, and provide potential solutions to the problems identified.
Collapse
Affiliation(s)
| | - Matthew T Roe
- Duke Clinical Research Institute, Durham, North Carolina
| | - Tariq Ahmad
- Duke Clinical Research Institute, Durham, North Carolina
| | - Peter Libby
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Jeffrey S Borer
- State University of New York Downstate Medical Center, Brooklyn, New York
| | | | | | - Milton Packer
- Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas
| | | | | | - Bertram Pitt
- University of Michigan School of Medicine, Ann Arbor, Michigan
| | - David L DeMets
- University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
| | - Katharine Cooper-Arnold
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Paul W Armstrong
- Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada
| | | | - Rob Scott
- Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas
| | - Jayne Prats
- The Medicines Company, Parsippany, New Jersey
| | - Zorina S Galis
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
| | - Norman Stockbridge
- Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland
| | | | | |
Collapse
|
8
|
McDonald CL. Dr. Sonia Skarlatos and the National Heart, Lung, and Blood institute translational research and resource programs. Hum Gene Ther 2013; 24:899-905. [PMID: 24164237 PMCID: PMC3815047 DOI: 10.1089/hum.2013.2511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Sonia I. Skarlatos, PhD (September 28, 1953-August 6, 2013), was the deputy director of the Division of Cardiovascular Sciences at the National Heart, Lung, and Blood Institute (NHLBI). This article reviews her work in establishing, leading, or facilitating extramural translational research programs supported by the NHLBI, specifically focusing on her work as a consistent advocate for the advancement of gene and cell therapies.
Collapse
Affiliation(s)
- Cheryl L McDonald
- Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda, MD 20892
| |
Collapse
|